2023-03-11
Phase II clinical trial of ImmuneOnco Biopharmaceuticals IMM0306 completes first subject enrollment for dosing
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the Phase II clinical trial of ImmuneOnco Biopharmaceuticals bispecific antibody-receptor re
View more